IP Library Granted Patent US 7,374,770
Granted Patent B2
US 7,374,770 · App. 10/219,087 · Granted May 20, 2008

Topical composition for follicular delivery of an ornithine decarboxylase inhibitor

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,374,770
App. No.
10/219,087
Granted
May 20, 2008
Kind
B2
Abstract

Polyethylene glycol ethers of alkyl alcohols having the general formula CH 3 (CH 2 ) x CH 2 (OCH 2 CH 2 ) n OH wherein x is 8 to 20 (of which ceteareth-20, steareth-20 and steareth-100 are preferred), poloxamer 185, poloxamer 407, N,N-dimethyl dodecylamine N-oxide, and mixtures thereof, are employed to increase follicular delivery and/or follicular residence time of certain water soluble ornithine decarboxylase inhibitors of which 2(difluoromethyl)-2,5-diamino pentanoic acid and its pharmaceutically acceptable salts, hydrates, optical enantiomers and racemic mixture are preferred.

Claims (29)

1. A topical composition for follicular delivery of an ornithine decarboxylase inhibitor to an area of mammalian skin containing hair follicles, the composition comprising:

a) an amount of an ornithine decarboxylase inhibitor selected from the group consisting of 2-(difluoromethyl)-2,5 -diaminopentanoic acid, alpha-ethynyl ornithine, 6heptyne-2,5-diamine,2-methyl-6-heptyne-2,5-diamine, and pharmaceutically acceptable salts, hydrates, optical enantiomers, and racemic mixtures thereof sufficient to deliver 1 to 2000 micrograms of the omithine decarboxylase inhibitor per square centimeter (cm 2 ) of the skin;

b) 1.0 to 25% of a follicular delivery enhancer, which provides a follicular enhancement ratio of at least 1.3 and is selected from the group consisting of poloxamer 185, poloxamer 407, N,N-dimethyl dodecylamine N-oxide, steareth-100, and mixtures thereof; and

c) a pharmaceutically acceptable carrier.

2. The composition, as claimed in claim 1 , wherein the inhibitor is 2-(difluoromethyl)-2,5-diaminopentanoic acid or a pharmaceutically acceptable salt, hydrate, (R) enantiomer, (S) enantiomer, or racemic mixture thereof.

3. The composition, as claimed in claim 1 , wherein the inhibitor is 2-(di fluoromethyl)-2,5-diaminopentanoic acid.

4. The composition, as claimed in claim 1 , wherein the ihhibitor is the R enantiomer of 2-(difluoromethyl)-2,5-diaminopentanoic acid.

5. The composition, as claimed in claim 1 , wherein the composition is a water-in-oil emulsion, an oil-in-water emulsion, a solution, a gel, a cream, a stick, an ointments a paste, a shampoo, a foam, a patch or a mousse.

6. The composition, as claimed in claim 1 , wherein the composition is an oil-in-water emulsion based lotion or cream.

7. The composition, as claimed in claim 1 , wherein the carrier is water and the composition is a solution.

8. The composition, as claimed in claim 1 , wherein the follicular delivery enhancer is present in an amount from 2.5% to 20% w/w based on the total weight of the composition.

9. The composition, as claimed in claim 1 , wherein the follicular delivery enhanceris present in an amount from 4% to 15% w/w based on the total weight of the composition.

10. The composition, as claimed in claim 1 , wherein the follicular delivery enhancer is present in an amount from 5% to 10% w/w based on the total weight of the composition.

11. The composition, as claimed in claim 1 , wherein the follicular delivery enhancer is present in an amount of at least 3% w/w based on the total weight of the composition.

12. The composition, as claimed in claim 1 , wherein the follicular delivery enhancer is present in an amount of at least4% w/w based on the total weight of the composition.

13. The composition, as claimed in claim 1 , wherein the follicular delivery enhancer comprises steareth-100.

14. The composition, as claimed in claim 13 , further comprising steareth-20.

15. The composition, as claimed in claim 1 , wherein the follicular delivery enhancer comprises poloxamer 185.

16. The composition, as claimed in claim 1 , wherein the follicular delivery enhancer comprises poloxamer 407.

17. The composition, as claimed in claim 1 , wherein the follicular delivery enhancer comprises N,N-dimethyl dodecylamine-N-oxide.

18. The composition, as claimed in claim 1 , further comprising an amount of an inhibitor of S-adenosyl methionine decarboxylase effective to reduce the rate and alter the character of mammalian hair growth.

19. The composition, as claimed in claim 18 , wherein the inhibitor of S-adenosyl methionine decarboxylase is selected from the group consisting of methylglyoxal bis (guanylhydrazone), diethylglyoxal bis (guanylhydrazone), and 5 ′-deoxy-5′-{N-methyl-N-}aminoadenosine.

20. The composition, as claimed in claim 14 , wherein 5% w/w steareth-20 and 5% w/w stearelh-100, based on the total weight of the composition, are present.

21. The composition, as claimed in claim 15 , where in the poloxamer 185 is present in an amount of 10% w/w based on the total weight of the composition.

22. The composition, as claimed in claim 16 , wherein poloxamer 407 is present in an amount of 10% w/w based on the total weight of the composition.

23. The composition, as claimed in claim 17 , wherein N,N-dimethyl dodecylamine N-oxide is present in an amount of 0.5% w/w based on the total weight of the composition.

24. The composition, as claimed in claim 14 , further comprising ceteareth-20.

25. The composition, as claimed in claim 24 , wherein 5% w/w steareth-20, 5% w/w steareth-100, and 2.5% w/w cetearyl alcohol and ceteareth-20, based on the total weight of the composition, are present.

26. The composition, as claimed in claim 14 , wherein the steareth-20 and steareth-100are present in a ratio of 1:1.

Assignments (9)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 5, 2013
From: SKINMEDICA, INC.
To: ALLERGAN, INC.
Reel/Frame 029752/0926 →
ASSIGNMENT OF RIGHTS AND QUITCLAIM Recorded Mar 6, 2006
From: CHOU, JOYCE T.; PARAB, PRAKASH V.; BRISTOL-MEYERS SQUIBB COMPANY; WOMEN FIRST HEALTHCARE, INC.
To: SKINMEDICA, INC.
Reel/Frame 017307/0755 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 18, 2005
From: WOMEN FIRST HEALTHCARE, INC.
To: SKINMEDICA, INC.
Reel/Frame 016536/0583 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 8, 2005
From: WOMEN FIRST HEALTHCARE, INC.
To: SKINMEDICA, INC.
Reel/Frame 016489/0331 →
BANKRUPTCY ORDER, SALE OF VANIGA FREE AND CLEAR OF ALL LIENS, CLAIMS AND ENCUMBRANCES, WITH EXHIBIT A Recorded Apr 25, 2005
From: WOMEN'S FIRST HEALTHCARE, INC.
To: SKINMEDICA, INC.
Reel/Frame 016497/0358 →
SECURITY AGREEMENT Recorded May 12, 2003
From: WOMEN FIRST HEALTHCARE, INC.
To: CIBC WMC INC.; WHITNEY PRIVATE DEBT FUND; J.H. WHITNEY MEZZANINE FUND, L.P.
Reel/Frame 014080/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 15, 2002
From: CHOU, JOYCE T.; PARAB, PRAKASH
To: WOMEN FIRST HEALTHCARE, INC.
Reel/Frame 013479/0386 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 13, 2002
From: CHOU, JOYCE T.; PARAB, PRAKASH
To: BRISTOL-MYERS SQUIBB COMPANY
Reel/Frame 013199/0259 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 13, 2002
From: BRISTOL-MYERS SQUIBB COMPANY
To: WOMEN FIRST HEALTHCARE, INC.
Reel/Frame 013199/0276 →